. 2019 Jun 11;8(7):935–940. doi: 10.1530/EC-19-0272
This work is licensed under a Table 1.
Comparison of secondary outcomes by treatment group.
| Parameter | Group n = 80 (total) | P value | ||
|---|---|---|---|---|
| Oestradiol alone (N = 21) | Cyproterone (N = 21) | Spironolactone (N = 38) | ||
| Urea (mmol/L) | 4.9 (4.2–5.8) | 4.2 (3.6–5.1) | 5.0 (4.3–6.0) | 0.035 |
| Creatinine (µmol/L) | 78 (72–96) | 72 (63–75) | 77 (69–85) | 0.069 |
| Oestradiol valerate dose (mg) | 6 (4–6) | 5 (4–6) | 6 (4–6) | 0.601 |
| Oestradiol concentration (pmol/L) | 256 (119–408) | 279 (149–334) | 279 (233–384) | 0.795 |
| BMI (kg/m2) | 27.2 (23.1–31.9) | 24.5 (23.4–30.3) | 24.7 (23.5–31.0) | 0.989 |
| Systolic BP (mmHg) | 125 (121–131) | 123 (118–136) | 125 (120–136) | 0.941 |
| Diastolic BP (mmHg) | 80 (75–81) | 85 (80–90) | 80 (75–82) | 0.056 |
| Haemoglobin (g/L) | 147 (143–159) | 148 (143–151) | 146 (138–158) | 0.880 |
| ALT (U/L) | 21 (15–28) | 23 (15–29) | 19 (14–24) | 0.630 |
Median (IQR) are presented. P values refer to overall difference between the groups and are obtained from the Kruskal–Wallis test as a non-parametric alternative to t-test.